Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.45 |
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17722662 | 1.00 | TMPRSS2 (0.45) | TMPRSS2POLRMTTRPM2SIRT2SIRT1 | |
| SCHEMBL26001843 | 0.92 | TMPRSS2 (0.40) | TMPRSS2POLRMTTRPM2SIRT2SIRT1 | |
| SCHEMBL17719210 | 0.89 | TMPRSS2 (0.40) | TMPRSS2TRPM2P2RY2P2RY6P2RY14 | |
| SCHEMBL17719238 | 0.88 | POLRMT (0.48) | TMPRSS2POLRMT | |
| SCHEMBL17719237 | 0.88 | TMPRSS2 (0.50) | TMPRSS2POLRMTTRPM2SIRT2SIRT1 | |
| SCHEMBL24917304 | 0.88 | TMPRSS2 (0.47) | TMPRSS2POLRMTP2RY2 | |
| SCHEMBL25909400 | 0.87 | TMPRSS2 (0.47) | TMPRSS2POLRMT | |
| SCHEMBL18298281 | 0.87 | TMPRSS2 (0.51) | TMPRSS2POLRMTTRPM2SIRT2SIRT1 | |
| Rdv-Tp SCHEMBL23278555 | 0.87 | POLRMT (0.51) | TMPRSS2POLRMT | |
| Rdv-Tp SCHEMBL10120881 | 0.87 | POLRMT (0.51) | TMPRSS2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | TMPRSS2 1951/4885POLRMT 104/4885TRPM2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.